01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – H.C. Wainwright Global Investment Conference August 27, 2024 – Posted in: Poolbeg Pharma (POLB)

27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually. The presentation will be available to view…

Continue reading

#POLB Poolbeg Pharma PLC – Significant POLB 001 Patent Granted in USA May 1, 2024 – Posted in: Poolbeg Pharma (POLB)

1 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.   The claims cover a class of drugs (including POLB 001) for treating hypercytokinaemia (cytokine…

Continue reading

#POLB Poolbeg Pharma PLC – Directorate Change November 30, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

30 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors. Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director…

Continue reading

#POLB Poolbeg Pharma PLC – POLB 001 LPS Trial Data to be Presented at IUIS November 16, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

16 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology (‘IUIS’), to be held 27 November – 2 December 2023 in Cape Town, South Africa. IUIS is the world’s…

Continue reading

#VELA investee co. #KING Igraine PLC – Interim Results for the Half-Year to 30 June 2023 September 29, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Interim Results for the Half-Year to 30 June 2023 Igraine plc, Directors Statement We are pleased to present the interim results for Igraine plc (AQUIS: KING) for the period ending 30 June 2023. This reporting period has unfolded in a challenging economic environment, but we are encouraged by the positive developments in our ongoing discussions and commercialisation efforts. Despite the economic headwinds, our maiden investment with Excalibur Medicines Ltd (“EML”) continues to progress positively. Igraine…

Continue reading

#TSP TruSpine Technologies PLC – Proposed Director Appointments & Update September 18, 2023 – Posted in: Blog, TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems announces the proposed appointments of Victoria Sena and Samuel Ogunsalu as Non-Executive Directors of the Company, subject to standard regulatory due diligence. Proposed Director Appointments Victoria Sena founded Cherrybank Consulting Limited in 2019 to assist clients in the areas of governance, operations, risk, and compliance. Previously Victoria spent eight years at the Bank of…

Continue reading

#VELA Vela Technologies PLC – Further update re. Economic Interest in AZD1656 September 8, 2023 – Posted in: Uncategorized

Further to the Company’s announcements on 15 August 2023 and 7 September 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that Murphy Canyon Acquisition Corp. (NASDAQ: MURF) (“Murphy”) announced yesterday that the special meeting of stockholders to approve, amongst other things, its initial business combination with Conduit Pharmaceuticals Limited has been postponed further and will now be held on 20 September 2023.  …

Continue reading

#VELA Vela Technologies PLC – Update re. Economic Interest in AZD1656 September 7, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Further to the Company’s announcement on 15 August 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that Murphy Canyon Acquisition Corp. (NASDAQ: MURF) (“Murphy”) has recently announced that the special meeting of stockholders to approve, amongst other things, its initial business combination with Conduit Pharmaceuticals Limited has been postponed and will now be held on 13 September 2023.   This meeting presents an…

Continue reading